Information Provided By: 
Fly News Breaks for June 11, 2015
ISIS
Jun 11, 2015 | 13:22 EDT
Piper Jaffray analyst Joshua Schimmer calls Isis Pharmaceuticals' (ISIS) ISIS-SMNRx data today "very encouraging," but says it's still difficult to interpret without a control arm. The sham-controlled Phase 3 program in collaboration with Biogen (BIIB) continues to enroll and data is expected 2016/2017, Schimmer tells investors. He reiterates a Neutral rating on Isis with a $68 price target, noting his model already assumes revenue for this program.
News For ISIS From the Last 2 Days
There are no results for your query ISIS
